Sequenom同汉堡-埃彭多夫医学中心合作开发结直肠癌液体活检新技术

  今天，Sequenom公司宣布，他们将同汉堡-埃彭多夫医学中心(University Medical Center Hamburg-Eppendorf，UKE)进行合作来评估液体活检技术在结直肠癌诊断治疗中的临床效用。
  目前Sequenom公司正在开发一种循环肿瘤DNA的检测技术，最初的目的在于对不易获得或风险性较高的组织样本中的晚期非血液性的恶性肿瘤进行检测并且进行分子特性的分析。
  在同UKE进行合作后，Sequenom将会具有一定的检测能力来帮助监测疗法对于晚期结直肠癌患者的效应； UKE已经进行了多年的ctDNA的研究，而且目前正在进行一系列不同的研究。
  这项合作将帮助Sequenom公司在质量和数量上对结直肠癌患者的血液中的体细胞突变进行检测评估，同时也可以帮助以一种非侵入性的方式来监测患者对疗法的反应。Sequenom公司的首席医疗官Daniel Grosu在一份声明中表示，同UKE的合作将帮助他们更好地理解循环肿瘤DNA的动态化改变，而这将会伴随开发一系列治疗结直肠癌的新型疗法，也将在一系列广谱的基因变化中奖肿瘤组织和血浆进行整合。
  Sequenom公司宣布，他们的目的是在今年年初开发ctDNA的检测手段，而且这是第三项临床试验后同学术机构达成的合作，早在这个月初，Sequenom公司就宣布同首尔大学医院进行合作，而且在8月他们也已经同加利福尼亚大学达成合作意向。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的原文摘要：

Sequenom, University Medical Center Hamburg-Eppendorf Collaborate on Liquid Biopsy
Sequenom will collaborate with the University Medical Center Hamburg-Eppendorf in Germany to evaluate the clinical utility of a liquid biopsy assay in colorectal cancer, the firm said today.

Sequenom is currently developing a circulating tumor DNA research assay with an initial focus on the detection and molecular profiling of late stage non-hematologic malignancies in cases where tissues biopsies are not available or are too risky to obtain.

In collaboration with Germany's UKE, Sequenom will test the assay' ability to monitor response to treatment in later-stage colorectal cancer patients. UKE has been studying ctDNA and circulating tumor cells for years and is currently involved in a number of different clinical studies, Klaus Pantel, chairman in the department of tumor biology at UKE's Center of Experimental Medicine, said in a statement.

The Sequenom collaboration will "allow us to qualitatively and quantitatively evaluate somatic mutations in the blood of colorectal cancer patients, and monitor response to treatment in a non-invasive manner," he said.

Daniel Grosu, Sequenom's chief medical officer, said in a statement that the study with UKE will help "better understand the dynamic changes in circulating tumor DNA that accompany the use of various treatments in later-stage colorectal cancer, and the concordance between tumor tissue and plasma across a broad spectrum of genomic alterations."

Sequenom announced its intention to develop a ctDNA assay at the beginning of the year and this is the third clinical deal it has since struck with academic collaborators. Earlier this month, Sequenom announced a deal with Seoul National University Hospital, and in August, it said it would work with the University of California, San Diego.